ATE460164T1 - Mittel zur behandlung von hyperlipidämie mit pitavastatinen und eicosapentaensäure - Google Patents
Mittel zur behandlung von hyperlipidämie mit pitavastatinen und eicosapentaensäureInfo
- Publication number
- ATE460164T1 ATE460164T1 AT05710692T AT05710692T ATE460164T1 AT E460164 T1 ATE460164 T1 AT E460164T1 AT 05710692 T AT05710692 T AT 05710692T AT 05710692 T AT05710692 T AT 05710692T AT E460164 T1 ATE460164 T1 AT E460164T1
- Authority
- AT
- Austria
- Prior art keywords
- pitavastatins
- agent
- treating hyperlipidemia
- eicosapentaenic acid
- acid
- Prior art date
Links
- 208000031226 Hyperlipidaemia Diseases 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 abstract 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 abstract 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 abstract 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 abstract 2
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 abstract 1
- 229960002797 pitavastatin Drugs 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/780,640 US7022713B2 (en) | 2004-02-19 | 2004-02-19 | Hyperlipemia therapeutic agent |
| PCT/JP2005/003092 WO2005079797A2 (en) | 2004-02-19 | 2005-02-18 | Hyperlipemia therapeutic agent comprising pitavastatins and eicosapentaenoic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE460164T1 true ATE460164T1 (de) | 2010-03-15 |
Family
ID=34860884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05710692T ATE460164T1 (de) | 2004-02-19 | 2005-02-18 | Mittel zur behandlung von hyperlipidämie mit pitavastatinen und eicosapentaensäure |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7022713B2 (de) |
| EP (1) | EP1715865B9 (de) |
| JP (1) | JP5474276B2 (de) |
| KR (1) | KR101376449B1 (de) |
| CN (1) | CN100475208C (de) |
| AT (1) | ATE460164T1 (de) |
| CY (1) | CY1110133T1 (de) |
| DE (1) | DE602005019856D1 (de) |
| DK (1) | DK1715865T3 (de) |
| ES (1) | ES2342609T3 (de) |
| PL (1) | PL1715865T3 (de) |
| PT (1) | PT1715865E (de) |
| SI (1) | SI1715865T1 (de) |
| WO (1) | WO2005079797A2 (de) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4719572B2 (ja) * | 2003-04-17 | 2011-07-06 | 興和株式会社 | Ｌｋｌｆ／ｋｌｆ２遺伝子発現促進剤 |
| US7022713B2 (en) * | 2004-02-19 | 2006-04-04 | Kowa Co., Ltd. | Hyperlipemia therapeutic agent |
| JP5069448B2 (ja) * | 2006-02-07 | 2012-11-07 | 持田製薬株式会社 | 脳卒中再発予防用組成物 |
| BRPI0621313A2 (pt) * | 2006-02-07 | 2011-12-06 | Mochilda Pharmaceutical Co Ltd | composição para previnir recorrência de acidente vascular cerebral |
| US8784886B2 (en) * | 2006-03-09 | 2014-07-22 | GlaxoSmithKline, LLC | Coating capsules with active pharmaceutical ingredients |
| US7728697B2 (en) * | 2006-09-26 | 2010-06-01 | Mg Materials Corporation | Systems and methods for electrically reducing ferroelectric materials to increase bulk conductivity |
| US20080085911A1 (en) * | 2006-10-10 | 2008-04-10 | Reliant Pharmaceuticals, Inc. | Statin and omega-3 fatty acids for reduction of apo-b levels |
| US20100119600A1 (en) * | 2007-06-01 | 2010-05-13 | Joar Opheim | Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof |
| KR20110039249A (ko) * | 2008-07-07 | 2011-04-15 | 모치다 세이야쿠 가부시키가이샤 | 지질 이상증의 개선 또는 치료약 |
| PL2334295T3 (pl) | 2008-09-02 | 2017-12-29 | Amarin Pharmaceuticals Ltd | Kompozycja farmaceutyczna zawierająca kwas eikozapentaenowy i kwas nikotynowy oraz sposoby jej zastosowania |
| KR20140007973A (ko) | 2009-02-10 | 2014-01-20 | 아마린 파마, 인크. | 고중성지방혈증 치료 방법 |
| CN104042617A (zh) | 2009-04-29 | 2014-09-17 | 阿马里纳药物爱尔兰有限公司 | 含有epa和心血管剂的药物组合物以及使用其的方法 |
| SG10201912687WA (en) | 2009-04-29 | 2020-02-27 | Amarin Pharmaceuticals Ie Ltd | Stable Pharmaceutical Composition And Methods Of Using Same |
| EP3698781A1 (de) | 2009-06-15 | 2020-08-26 | Amarin Pharmaceuticals Ireland Limited | Zusammensetzungen mit eicosapentaensäure zur behandlung von myokardinfarktionen bei patienten mit gleichzeitiger statin-therapie |
| RU2758369C2 (ru) | 2009-09-23 | 2021-10-28 | Амарин Фармасьютикалз Айрлэнд Лимитед | Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина, и способы ее применения |
| JP5951489B2 (ja) * | 2009-10-16 | 2016-07-13 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | 組成物 |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| NZ744990A (en) | 2010-11-29 | 2019-10-25 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| WO2013070735A1 (en) | 2011-11-07 | 2013-05-16 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US9827219B2 (en) | 2012-01-06 | 2017-11-28 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity C-reactive protein (HS-CRP) in a subject |
| LT4338805T (lt) | 2012-06-29 | 2025-09-25 | Amarin Pharmaceuticals Ireland Limited | Eikozapentaeno rūgšties etilo esteris, skirtas panaudoti mažinant nemirtino miokardo infarkto riziką subjektui, gydomam statinais |
| CN102824636A (zh) * | 2012-08-15 | 2012-12-19 | 四川大学 | 一种含他汀类药物和多不饱和脂肪酸的药物组合物及其用途 |
| US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US9895332B2 (en) | 2013-10-30 | 2018-02-20 | Patheon Softgels, Inc. | Enteric soft capsules comprising polyunsaturated fatty acids |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| US9895333B2 (en) | 2014-06-26 | 2018-02-20 | Patheon Softgels Inc. | Enhanced bioavailability of polyunsaturated fatty acids |
| WO2015200563A1 (en) * | 2014-06-26 | 2015-12-30 | Banner Life Sciences Llc | Enhanced bioavailability of polysaturated fatty acids |
| WO2016026139A1 (zh) * | 2014-08-22 | 2016-02-25 | 财团法人国防教育研究基金会 | 用于治疗非酒精性脂肪肝疾病的药物及应用 |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| US10600502B2 (en) | 2016-12-20 | 2020-03-24 | Astrazeneca Uk Ltd. | Systems and methods for dispensing a statin medication over the counter |
| TW201900160A (zh) | 2017-05-19 | 2019-01-01 | 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 | 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法 |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| EP3750535B1 (de) | 2018-09-24 | 2025-12-31 | Amarin Pharmaceuticals Ireland Limited | Verfahren zur verringerung des risikos von kardiovaskulären ereignissen in einem subjekt |
| BR112022009189A2 (pt) | 2019-11-12 | 2022-07-26 | Amarin Pharmaceuticals Ie Ltd | Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial |
| US20220008519A1 (en) | 2020-07-09 | 2022-01-13 | Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) | Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho |
| AU2022263358A1 (en) | 2021-04-21 | 2023-11-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2569746B2 (ja) * | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
| GB8819110D0 (en) * | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
| US5861399A (en) * | 1996-07-17 | 1999-01-19 | Heart Care Partners | Methods and compositions for the rapid and enduring relief of inadequate myocardial function |
| CN1109543C (zh) * | 1996-10-11 | 2003-05-28 | 斯卡里斯塔有限公司 | 包括二十碳五烯酸和/或十八碳四烯酸的药物制剂 |
| US6083497A (en) * | 1997-11-05 | 2000-07-04 | Geltex Pharmaceuticals, Inc. | Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers |
| US6777552B2 (en) * | 2001-08-16 | 2004-08-17 | Teva Pharmaceutical Industries, Ltd. | Processes for preparing calcium salt forms of statins |
| US6982251B2 (en) * | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| CN1370544A (zh) * | 2001-02-27 | 2002-09-25 | 张洪超 | 一种具有降血脂作用的林蛙卵油营养保健胶囊及其制法 |
| EP1425287A4 (de) * | 2001-08-16 | 2005-09-07 | Teva Pharma | Verfahren zur herstellung von calciumsalzformen von statinen |
| CN1197564C (zh) * | 2001-09-30 | 2005-04-20 | 中国药品生物制品检定所 | 海狗油在制备治疗脂代谢紊乱药物中的应用 |
| EP1534243A4 (de) * | 2002-08-26 | 2008-08-13 | Lipid Sciences Inc | Behandlung von alzheimer mit entlipidierten protein-teilchen |
| US7022713B2 (en) * | 2004-02-19 | 2006-04-04 | Kowa Co., Ltd. | Hyperlipemia therapeutic agent |
-
2004
- 2004-02-19 US US10/780,640 patent/US7022713B2/en not_active Expired - Lifetime
-
2005
- 2005-02-18 KR KR1020067016099A patent/KR101376449B1/ko not_active Expired - Fee Related
- 2005-02-18 CN CNB2005800053563A patent/CN100475208C/zh not_active Expired - Fee Related
- 2005-02-18 SI SI200531022T patent/SI1715865T1/sl unknown
- 2005-02-18 EP EP05710692A patent/EP1715865B9/de not_active Expired - Lifetime
- 2005-02-18 AT AT05710692T patent/ATE460164T1/de active
- 2005-02-18 DE DE602005019856T patent/DE602005019856D1/de not_active Expired - Lifetime
- 2005-02-18 DK DK05710692.4T patent/DK1715865T3/da active
- 2005-02-18 WO PCT/JP2005/003092 patent/WO2005079797A2/en not_active Ceased
- 2005-02-18 JP JP2006525561A patent/JP5474276B2/ja not_active Expired - Fee Related
- 2005-02-18 ES ES05710692T patent/ES2342609T3/es not_active Expired - Lifetime
- 2005-02-18 PL PL05710692T patent/PL1715865T3/pl unknown
- 2005-02-18 PT PT05710692T patent/PT1715865E/pt unknown
- 2005-12-05 US US11/293,217 patent/US7776881B2/en not_active Expired - Fee Related
-
2010
- 2010-06-03 CY CY20101100490T patent/CY1110133T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN100475208C (zh) | 2009-04-08 |
| CY1110133T1 (el) | 2015-01-14 |
| EP1715865A2 (de) | 2006-11-02 |
| EP1715865B1 (de) | 2010-03-10 |
| EP1715865B8 (de) | 2010-05-19 |
| KR101376449B1 (ko) | 2014-03-19 |
| CN1921860A (zh) | 2007-02-28 |
| JP2007523049A (ja) | 2007-08-16 |
| PL1715865T3 (pl) | 2010-09-30 |
| KR20060109988A (ko) | 2006-10-23 |
| DE602005019856D1 (de) | 2010-04-22 |
| DK1715865T3 (da) | 2010-05-10 |
| JP5474276B2 (ja) | 2014-04-16 |
| US7022713B2 (en) | 2006-04-04 |
| WO2005079797A3 (en) | 2006-05-11 |
| HK1098953A1 (zh) | 2007-08-03 |
| PT1715865E (pt) | 2010-04-01 |
| SI1715865T1 (sl) | 2010-08-31 |
| WO2005079797A2 (en) | 2005-09-01 |
| US20050187292A1 (en) | 2005-08-25 |
| US20060111437A1 (en) | 2006-05-25 |
| US7776881B2 (en) | 2010-08-17 |
| EP1715865B9 (de) | 2010-12-15 |
| ES2342609T3 (es) | 2010-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE460164T1 (de) | Mittel zur behandlung von hyperlipidämie mit pitavastatinen und eicosapentaensäure | |
| DE602005019319D1 (de) | Zusammensetzungen mit ornithin und phenylacetat oder phenylbutyrat zur behandlung von hepatischer enzephalopathie | |
| AR109605A2 (es) | Método para tratar enfermedades vasculares periféricas, composición y utilización | |
| DE502007002101D1 (de) | Arzneimittel mit Dobesilat-Calcium zur Behandlung und Prophylaxe von Sehnenerkrankungen | |
| EA200800356A1 (ru) | Лечение ингибиторами абсорбции холестерина на основе азетидинона и омега-3 жирными кислотами и их комбинированным препаратом | |
| DE602007006815D1 (de) | 4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl-pyridin-3-ylamino)-pyrimidin-4-yloxyü-piperidin-1-carbonsäure isopropyl ester als stoffwechselmodulatore und behandlung von damit assoziierten erkrankungen | |
| EP1622608A4 (de) | Zusammensetzungen und verfahren zur behandlung von krebs | |
| ATE551996T1 (de) | Behandlung oder prävention von diabetes mit cannabidiol | |
| ATE376828T1 (de) | Verwendung von rotigotin zur behandlung und prävention des parkinson-plus-syndroms | |
| DE602004010708D1 (de) | Imidazopyridinsubstituierte tropanderivate mit ccr5-rezeptorantagonistischer wirkung zur behandlung von hiv und entzündungen | |
| WO2010036395A3 (en) | Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds | |
| EA200970483A1 (ru) | Применение пролекарств габапентина и прегабалина для лечения шума в ушах | |
| DE60330161D1 (de) | Rifalazil zur behandlung von infektionen mit clostridium difficile | |
| EP1742675A4 (de) | Behandlung von biomedizinischem abfall | |
| WO2007041398A3 (en) | Treatment of cancer with specific rxr agonists | |
| EP3351211C0 (de) | Sklerale prothese zur behandlung von altersweitsichtigkeit und anderen augenerkrankungen | |
| EA200970529A1 (ru) | Антивирусная композиция и способ ее применения | |
| ATE447551T1 (de) | Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen | |
| ATE548035T1 (de) | Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat | |
| EP1905452A4 (de) | Wirkstoff zur prävention oder behandlung von glaukomen | |
| EP1844779A3 (de) | Tergurid/Protergurid zur Behandlung von chronischen Schmerzen (z.B. Migräne) | |
| WO2008027880A3 (en) | Strontium-based treatment of otosclerosis | |
| ATE406171T1 (de) | Aplidine zur behandlung von multiplem myelom | |
| ATE445644T1 (de) | Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten | |
| CY1110156T1 (el) | Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1715865 Country of ref document: EP |